These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25043434)

  • 21. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choice of maintenance medication for schizophrenia.
    Davis JM; Chen N
    J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
    Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
    Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Guidelines for the use of second-generation long-acting antipsychotics].
    Jarema M; Wichniak A; Dudek D; Samochowiec J; Bieńkowski P; Rybakowski J
    Psychiatr Pol; 2015; 49(2):225-41. PubMed ID: 26093588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.
    Voss EA; Ryan PB; Stang PE; Hough D; Alphs L
    Int Clin Psychopharmacol; 2015 May; 30(3):151-7. PubMed ID: 25730525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.